2nd Feb 2016 07:57
LONDON (Alliance News) - Investment company Imperial Innovations Group PLC on Tuesday said it has committed to the GBP60.0 million funding round by portfolio company MISSION Therapeutics.
The financing round was led by Imperial and Woodford Patient Capital Trust PLC, the fund run by prominent fund manager Neil Woodford.
Imperial committed an GBP11.3 million investment to the funding round, increasing its stake in MISSION to 22%.
MISSION is a drug development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
WPCT.LImperial Innovations Group